Open access

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022-2023 and 2023-2024 seasons.

Mahrukh Imran B. Chastek T. Bancroft Noah Webb S. Pelton Mendel D. M. Haag I. McGovern

Aug 2026 · International Journal of Infectious Diseases · Vol 171, pp. 109025 · 0 citations · 20 references

Medicine

TL;DR

AQIV and HD-QIV provided comparable protection for prevention of test-confirmed influenza among older adults in any and ED/hospitalization settings in the 2023-2024 season and for hospitalizations in overall and high-risk older adults in pooled 2022-2024 analyses.

Abstract

Objectives

Evaluate relative vaccine effectiveness (rVE) of adjuvanted quadrivalent influenza vaccine (aQIV) versus high-dose QIV (HD-QIV) in preventing test-confirmed influenza during 2023-2024 in any setting and emergency department (ED)/hospitalization settings, as well as in preventing hospitalizations in overall and high-risk older adults in a pooled analysis from 2022-2024.

Methods

This retrospective test-negative design study included US adults aged ≥65 years vaccinated with aQIV or HD-QIV who presented with acute respiratory or febrile illness and were tested for influenza per routine care. The rVE of aQIV versus HD-QIV was evaluated combining inverse probability of treatment weighting and logistic regression to adjust for potential confounders.

Results

The 2023-2024 season included 37,377 vaccinated and tested individuals (3,174 cases; 34,203 controls). rVE of aQIV versus HD-QIV was -0.9% (95% CI: -9.9, 7.3) in any setting and 0.5% (-12.1, 11.6) in ED/hospitalization settings. For pooled analyses of hospitalizations, rVE was -0.5% (-13.4, 10.9) overall and -1.3% (-14.4, 10.4) in the high-risk subgroup.

Conclusions

aQIV and HD-QIV provided comparable protection for prevention of test-confirmed influenza among older adults in any and ED/hospitalization settings in the 2023-2024 season and for hospitalizations in overall and high-risk older adults in pooled 2022-2024 analyses.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Sep 2026

Influenza vaccine effectiveness against influenza-related medical visits, hospitalization and death among adults aged 65 years and older in Taiwan: interim 2024-2025 season result using standard-dose inactivated influenza vaccine.

BACKGROUND The 2024-2025 influenza season in Taiwan was notably more severe than the prior season, with severe cases increasing from 1433 to 2215 and deaths increasing from 297 to 545. Vaccination coverage among adults aged ≥65 years also declined from 53.6% to 48.1%. All government-funded vaccines in the 2024-2025 sea...

Tsung-Pei Tsou, Yi-Ting Huang, Chieh-Yu Lin et al. · Vaccine · 0 citations

Open access Oct 2026

Absolute and Relative Effectiveness of High-Dose vs Standard-Dose Influenza Vaccines Against Severe Outcomes in Older Adults

Importance Several influenza vaccine products are available for older adults, but evidence combining both their absolute effectiveness and head-to-head comparisons within the same large population remains scarce, limiting product-specific vaccination guidance for this high-risk group. Objective To estimate the relative...

S. Le Vu, N. Gutierrez-Melo, T. Cartailler et al. · medRxiv · 0 citations

Review Open access Oct 2026

Adjuvanted Influenza Vaccines Versus Other Influenza Vaccines in Adults Aged ≥60 Years: A Systematic Review and Meta-Analysis of Relative Effectiveness for Preventing Influenza-Related Hospitalization

Background/Objectives: Seasonal influenza vaccines have been developed to reduce the risk of severe complications in older adults, who are at increased risk of influenza-related morbidity and mortality. This study aimed to synthesize the available evidence on the comparative effectiveness of MF59-adjuvanted versus high...

Daniela Amicizia, F. Marchini, I. Schenone et al. · Vaccines · 0 citations

Open access Aug 2026

Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.

Vaccination showed little or no association with ICU admission, but was associated with a one-quarter reduction in IHD among hospitalized older adults, reinforcing its benefits against fatal in-hospital outcomes.

Diogo F. P. Marques, Angela M. C. Rose, S. Monge et al. · Expert Review of Vaccines · 0 citations

Open access

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty...

C. Espersen, N. Johansen, D. Modin et al. · The Lancet Healthy Longevity · 0 citations

Open access Sep 2026

Real-World Effectiveness of Influenza Vaccination Against Medically Attended Influenza and Severe Outcomes Among Older Adults in Yichang, China: A Multi-Season Population-Based Cohort Study

Background/Objectives: Real-world evidence on influenza vaccine effectiveness (VE) against severe outcomes among older adults in China remains limited. We evaluated influenza vaccination against medically attended influenza, influenza hospitalization, and influenza-related intensive care unit (ICU) admission among adul...

Guan-Qi Wang, Hong Cao, Yi Yan et al. · Vaccines · 0 citations